Tanke Biosciences Corp (TNBI)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2012, Tanke Biosciences Corp reported revenue of $28.56M, up 19.8% from the prior year. The company ran a net loss, with a net margin of -0.8% and a gross margin of 34.8%. It held $28.85M in total assets against $12.93M in total liabilities.
Key ratios (FY2012)
34.8%
Gross margin
15.9%
Operating margin
-0.8%
Net margin
-1.4%
Return on equity
+19.8%
Revenue growth (YoY)
| Metric (FY) | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|
| Revenue | $28.56M | $23.83M | $20.10M | — | — |
| Cost of Revenue | $18.62M | $15.06M | $12.70M | — | — |
| Gross Profit | $9.94M | $8.77M | $7.40M | — | — |
| Operating Income | $4.53M | $1.74M | $4.37M | — | — |
| Net Income | -$229.0K | -$3.14M | $3.69M | $2.58M | — |
| EPS (Diluted) | — | $-0.24 | $0.34 | — | — |
| Total Assets | $28.85M | $24.89M | $13.27M | — | — |
| Total Liabilities | $12.93M | $9.03M | $2.93M | — | — |
| Shareholders' Equity | $15.92M | $15.85M | $10.33M | $6.44M | $3.77M |
| Cash & Equivalents | $6.17M | $7.70M | $2.22M | $1.82M | — |
| Operating Cash Flow | -$1.18M | $3.65M | $4.38M | — | — |
| Capital Expenditures | $856.4K | $701.0K | $76.1K | — | — |
| Shares Outstanding | 13.32M | 13.32M | 10.76M | — | — |